Research identifies new therapeutic target for Alzheimer's disease
Research led by Chu Chen, PhD, Associate Professor of Neuroscience at LSU Health Sciences Center New Orleans, has identified an enzyme called Monoacylglycerol lipase (MAGL) as a new therapeutic target to treat or prevent Alzheimer's disease. The study was published online November 1, 2012 in the Online Now section of the journal Cell Reports.
The research team found that inactivation of MAGL, best known for its role in degrading a cannabinoid produced in the brain, reduced the production and accumulation of beta amyloid plaques, a pathological hallmark of Alzheimer's disease. Inhibition of this enzyme also decreased neuroinflammation and neurodegeneration, and improved plasticity of the brain, learning and memory.
"Our results suggest that MAGL contributes to the cause and development of Alzheimer's disease and that blocking MAGL represents a promising therapeutic target," notes Dr. Chu Chen, who is also a member of the Department of Otolaryngology at LSU Health Sciences Center New Orleans.
The researchers blocked MAGL with a highly selective and potent inhibitor in mice using different dosing regimens and found that inactivation of MAGL for eight weeks was sufficient to decrease production and deposition of beta amyloid plaques and the function of a gene involved in making beta amyloid toxic to brain cells. They also measured indicators of neuroinflammation and neurodegeneration and found them suppressed when MAGL was inhibited. The team discovered that not only did the integrity of the structure and function of synapses associated with cognition remain intact in treated mice, but MAGL inactivation appeared to promote spatial learning and memory, measured with behavioral testing.
Alzheimer's disease is a neurodegenerative disorder characterized by accumulation and deposition of amyloid plaques and neurofibrillary tangles, neuroinflammation, synaptic dysfunction, progressive deterioration of cognitive function and loss of memory in association with widespread nerve cell death. The most common cause of dementia among older people, more than 5.4 million people in the United States and 36 million people worldwide suffer with Alzheimer's disease in its various stages. Unfortunately, the few drugs that are currently approved by the Food and Drug Administration have demonstrated only modest effects in modifying the clinical symptoms for relatively short periods, and none has shown a clear effect on disease progression or prevention.
"There is a great public health need to discover new therapies to prevent and treat this devastating disorder," Dr. Chen concludes. The research was supported by grants from the National Institutes of Health. In addition to scientists from LSU Health Sciences Center New Orleans, the research team also included investigators from the Massachusetts Institute of Technology.
Journal reference: Cell Reports
Provided by Louisiana State University
- Road block as a new strategy for the treatment of Alzheimer's Aug 22, 2011 | not rated yet | 0
- Inflammatory mediator enhances plaque formation in Alzheimer's disease Sep 07, 2011 | not rated yet | 0
- New target identified for Alzheimer’s disease Sep 29, 2010 | not rated yet | 0
- Scientists identify a new target for Alzheimer's disease Sep 21, 2010 | not rated yet | 0
- Researchers identify new enzyme to fight Alzheimer's disease Sep 17, 2012 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Calculus of Variation - Classical Mechanics
1 hour ago I'm reading Classical Mechanics (Taylor), and the 6th chapter is a basic introduction to calculus of variations. I'm super confused :confused: ...
Frictional Force Equation Doesn't Make Sense
1 hour ago Frictional Force is mathematically defined as: Ff = μ*m*g*cos(θ) , where μ is the coefficient of friction, m is the mass of the object, g is...
Calculating Steam Pressure in Closed Container
6 hours ago I am trying to calculate the volume of liquid water i need to place in a sealed container in order to obtain 10 psi of steam pressure in that closed...
Learning curve of Electromagnetism?
12 hours ago I'm taking a first year physics course and have been having a little trouble with the basics of newtons laws and forces and whatnot, though nothing...
thin glass in liquid
13 hours ago I have one question about optics because I start interested in it. If an object is placed a distance p from a thin glass lens (index of refraction...
How many joules expended for a push up?
16 hours ago Just wondering if any of you can do the calculation that well approximates the amount of joules expended by a push up.
- More from Physics Forums - Classical Physics
More news stories
(Medical Xpress)—Working with lab mice models of multiple sclerosis (MS), UC Davis scientists have detected a novel molecular target for the design of drugs that could be safer and more effective than current FDA-approved ...
Alzheimer's disease & dementia May 17, 2013 | 5 / 5 (2) | 0 |
(HealthDay)—Older individuals with nonmelanoma skin cancer (NMSC) seem to have a significantly reduced risk of developing Alzheimer's disease (AD), according to a study published online May 15 in Neurology.
Alzheimer's disease & dementia May 16, 2013 | 5 / 5 (1) | 0
People who have skin cancer may be less likely to develop Alzheimer's disease, according to new research published in the May 15, 2013, online issue of Neurology®, the medical journal of the American Academy of Neurology. The li ...
Alzheimer's disease & dementia May 15, 2013 | 5 / 5 (1) | 0 |
(Medical Xpress)—Scientists at Washington University School of Medicine in St. Louis have helped identify many of the biomarkers for Alzheimer's disease that could potentially predict which patients will develop the disorder ...
Alzheimer's disease & dementia May 14, 2013 | 3 / 5 (1) | 0 |
A drug developed by scientists at the Salk Institute for Biological Studies, known as J147, reverses memory deficits and slows Alzheimer's disease in aged mice following short-term treatment. The findings, ...
Alzheimer's disease & dementia May 13, 2013 | 4.2 / 5 (5) | 0 |
Regular consumption of coffee is associated with a reduced risk of primary sclerosing cholangitis (PSC), an autoimmune liver disease, Mayo Clinic research shows. The findings were being presented at the Digestive Disease ...
1 hour ago | not rated yet | 0 |
Patients with treatment-resistant major depression saw dramatic improvement in their illness after treatment with ketamine, an anesthetic, according to the largest ketamine clinical trial to-date led by researchers from the ...
1 hour ago | 4.5 / 5 (2) | 0 |
Research presented at Digestive Disease Week (DDW) explores new methods for managing digestive health through diet and lifestyle.
54 minutes ago | not rated yet | 0
There are significant cost and risk factors associated with two procedures commonly used to diagnose or treat gastrointestinal problems, according to research presented at Digestive Disease Week (DDW).
44 minutes ago | not rated yet | 0
The use of a smartphone application significantly improves patients' preparation for a colonoscopy, according to new research presented today at Digestive Disease Week (DDW). The preparation process, which begins days in ...
34 minutes ago | not rated yet | 0
An increasing number of U.S. children are experiencing gastrointestinal issues that require interventions to resolve, according to research presented at Digestive Disease Week (DDW).
15 hours ago | not rated yet | 0 |